Please ensure Javascript is enabled for purposes of website accessibility

Why Zomedica Stock Popped Today

By Joe Tenebruso - Jan 25, 2021 at 1:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The veterinary technology specialist is strengthening its distribution network.

What happened 

Shares of Zomedica (ZOM 10.58%) rose on Monday after the veterinary health company signed a new distribution agreement for its Truforma diagnostic platform. As of 1:25 p.m. EST, Zomedica's stock price was up nearly 7% after rising as much as 14% earlier in the day. 

So what

Zomedica struck a deal with Miller Veterinary Supply. The wholesale veterinary distributor will work with Zomedica's salesforce to drive sales of Truforma in the eastern region of the U.S. Miller will also provide customer service support for the point-of-care diagnostics system for cats and dogs.

A veterinarian is holding a small black-and-white dog.

Zomedica is preparing for the upcoming commercial launch of its Truforma veterinary diagnostics system. Image source: Getty Images.

"We could not be happier about signing this distribution agreement with such a reputable and highly experienced organization," Zomedica CEO Robert Cohen said in a press release. "We believe that the principals of Miller share the same commitment to quality, customer service, and value that we hope to be hallmarks of the Truforma line of products."

Now what

Zomedica will begin selling its Truforma systems on March 30. The patented diagnostic platform is expected to produce precise and reliable results when used to detect diseases in dogs and cats. Zomedica thus expects Truforma to enjoy strong demand in the veterinary marketplace. 

"It isn't often that an industry-changing product like Truforma comes along," Miller Chief Operating Officer Clay Cass said. "We are honored and excited to have been chosen to help bring this technology to market."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
$0.24 (10.58%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.